Drug Trial Radar · NCT07877155
To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Nov 3, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Hemay Pharmaceutical PTY. LTD.Industry
- Sponsor type
- Industry
- First posted
- Oct 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and efficacy of Hemay5394 in patients with mild to moderate atopic dermatitis
Conditions
- Safety
- Efficiency
Interventions
Hemay5394 groupDrug
investigational product,Topical administration, twice daily
Control groupDrug
Compared with the experimental group,Topical administration, twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving Eczema Area and Severity Index (EASI)-75Time frame: Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Innovate Clinical Research
Waitara, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.